SEARCH

SEARCH BY CITATION

References

  • 1
    Zou S, Stramer SL, Notari EP, Kuhns MC, Krysztof D, Musavi F, Fang CT, Dodd RY. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009;49:1609-1620.
  • 2
    Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, Stramer SL. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010;50:1495-1504.
  • 3
    Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, Nemo GJ, Busch MP. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003;43:788-798.
  • 4
    Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain JP, Gerlich W. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011;364:236-247.
  • 5
    Stramer SL, Zou S, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value? Transfusion 2012;52:440-446.
  • 6
    Stramer SL, Krysztof DE, Brodsky JP, Fickett TA, Reynolds B, Phikulsod S, Oota S, Lin M, Saldanha J, Kleinman SH. Sensitivity comparison of two Food and Drug Administration-licensed, triplex nucleic acid test automated assays for hepatitis B virus DNA detection and associated projections of United States yield. Transfusion 2011;51:2012-2022.
  • 7
    Stramer SL, Krysztof DE, Brodsky J, Fickett T, Reynolds B, Kleinman SH. Comparative analysis of triplex NAT assays in US blood donors. Transfusion 2013;53:2525-2537.
  • 8
    Gen-Probe, Incorporated. Procleix® Ultrio® Assay product insert: 502165, Rev. A. 2011. San Diego CA, USA.
  • 9
    US Food and Drug Administration. Guidance for industry: use of nucleic acid tests on pooled and individual samples from donors of whole blood and blood components, including source plasma, to reduce the risk of transmission of hepatitis B virus. Oct 2012 [cited 2012 Dec 2]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm327850.htm
  • 10
    Roche Molecular Systems, Inc. cobas® Ampliscreen HBV Test, product insert: 03599779 190, Rev. 4. 10/2007. Branchburg NJ, USA.
  • 11
    Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006;36(Suppl 1):S23-29.
  • 12
    Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K. Infectivity of blood components with low hepatitis B virus DNA levels identified in a look back program. Transfuson 2007;47:1197-1205.
  • 13
    Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol 2008;48:1022-1025.
  • 14
    Allain J-P, Mihaljevic I, Gonzáles Fraile M, Gubbe K, Garci JM, Brojer E, Erikstrup C, Saniewski M, Wernisch L, Blanco Peris L, Ulum H, Candotti D, Lelie N, Gerlich W, Chudy M. Infectivity of blood products from donors with occult hepatitis B infection (OBI). Transfusion 2013;53:1405-1415.
  • 15
    Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009;49:2454-2489.
  • 16
    Tabuchi A, Tanaka J, Katayama K, Mizui M, Matsukura H, Yugi H, Shimada T, Miyakawa Y, Yoshizawa H. Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. J Med Virol 2008;80:2064-2068.
  • 17
    Vermeulen M, Dickens C, Lelie N, Walker E, Coleman C, Keyter M, Reddy R, Crookes R, Kramvis A. Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion 2012;52:88-92.
  • 18
    Gen-Probe, Incorporated. Procleix® Ultrio Plus® Assay product insert: 502432, Rev. 7. 2012. San Diego CA, USA.
  • 19
    Roth WR, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, Jungbauer C, Minsk PM, Sondag-Thull D, Wendel S, Levi JE, Fearon M, Delage G, Xie Y, Jukić I, Turek P, Ullum H, Tefanova V, Tilk M, Reimal R, Castren J, Naukkarinen M, Assal A, Jork C, Reesink HW et al. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012;102:82-90.